← All Edwards Lifesciences CORP filings

Edwards Lifesciences CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NYSE
EW
Edwards Lifesciences CORP
10-K: Edwards Lifesciences Reports Strong 2025 Sales Growth
Edwards Lifesciences reported a significant increase in net sales for 2025, driven by strong performance in its TAVR and TMTT product groups, despite a decrease in net income due to higher operational and litigation expenses.
NYSE
EW
Edwards Lifesciences CORP
10-K: Edwards Lifesciences Reports Strong 2024 Results, Driven by TAVR and TMTT Growth
Edwards Lifesciences' 2024 annual report highlights a strong financial year with increased net sales and strategic moves including the sale of its Critical Care product group and acquisitions to bolster its structural heart portfolio.
NYSE
EW
Edwards Lifesciences CORP
10-K: Edwards Lifesciences Outlines Employee Agreement and Financial Performance in 10-K Filing
Edwards Lifesciences' 10-K filing details an employment agreement focusing on confidentiality and competition, alongside a review of the company's financial performance and strategic direction.